Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition

9 Jun 2025

Abstract excerpt

MET-targeted therapies are the most effective treatment for patients with MET-amplified lung cancer. However, acquired drug resistance is a significant challenge in MET-amplified lung cancer treatment. This study aimed to discover an effective treatment strategy for overcoming MET-targeted drug resistance. We first established a lung cancer cell line resistant to MET tyrosine kinase inhibitor (MET-TKI) (H1993...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Liver physiology and pathology
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40499687
DOI: 10.1016/j.bbamcr.2025.120001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibitionPMID 40499687Read ↗

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.Semantic proximity Read ↗

[Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations].Semantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

[Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

High expression of Aurora-B is correlated with poor prognosis and drug resistance in non-small cell lung cancerSemantic proximity Read ↗

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.Semantic proximity Read ↗

Progress on treatment of MET signaling pathway in non-small cell lung cancer.Semantic proximity Read ↗

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER 2 alterationsSemantic proximity Read ↗

Alisertib inhibits migration and invasion of EGFR-TKI resistant cells by partially reversing the epithelial-mesenchymal transition.Semantic proximity Read ↗

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapySemantic proximity Read ↗

Design, synthesis, and evaluation of dual EGFR/AURKB inhibitors as anticancer agents for non-small cell lung cancer.Semantic proximity Read ↗

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.